Leadership Overview
Asymchem has 4 executives leading key functions including strategy, technology, revenue, and operations.
Driven by innovation, Asymchem is dedicated to advancing drug development and manufacturing services for global pharmaceutical companies, specializing in green solutions and positioning itself as a preferred partner in the sector.
Driven by innovation, Asymchem is dedicated to advancing drug development and manufacturing services for global pharmaceutical companies, specializing in green solutions and positioning itself as a preferred partner in the sector.
Leadership Roles at Asymchem
Hao Hong - Chief Executive Officer
Hao Hong, the Chief Executive Officer at Asymchem, directs the overarching corporate strategy and operational execution. Hong guides Asymchem's mission to provide innovative green solutions and advanced drug development and manufacturing services to global pharmaceutical clients. This leadership role involves aligning departmental objectives with the company's commitment to sustainability and client success. Hong ensures that Asymchem maintains its position as a preferred partner within the pharmaceutical sector by fostering a culture of continuous improvement and client-centric service delivery. The Chief Executive Officer's strategic vision shapes Asymchem's market approach and long-term growth trajectory, focusing on expanding capabilities and enhancing service offerings to meet evolving industry demands. Hao Hong's leadership drives the company's expansion and reinforces its reputation for excellence in pharmaceutical manufacturing.
Elut Hsu - President
Elut Hsu, the President at Asymchem, oversees the strategic direction and operational management of the organization. Hsu guides Asymchem's commitment to serving global pharmaceutical companies with advanced drug development and manufacturing services, emphasizing innovative green solutions. This leadership position involves ensuring seamless integration of all business functions to meet client requirements and uphold the company's reputation for excellence. The President's focus is on driving operational efficiency and fostering strategic partnerships that enhance Asymchem's market presence. Hsu plays a crucial role in translating the company's mission into tangible results, ensuring that Asymchem remains a preferred partner for pharmaceutical innovation and production. Elut Hsu's comprehensive oversight supports Asymchem's growth and its dedication to sustainable practices in the pharmaceutical sector.
Cheng Chen - Chief Technology Officer
Cheng Chen, the Chief Technology Officer at Asymchem, spearheads technological innovation and the development of advanced manufacturing processes. Chen oversees the integration of cutting-edge green chemistry solutions and novel drug development technologies across all operational facets. This involves driving research and development initiatives to enhance Asymchem's service portfolio, ensuring clients receive state-of-the-art support in drug production. The Chief Technology Officer's expertise is critical in maintaining Asymchem's competitive edge by optimizing manufacturing efficiency and sustainability. Chen collaborates with cross-functional teams to translate scientific advancements into scalable, reliable manufacturing solutions. Cheng Chen's technical leadership ensures Asymchem remains at the forefront of pharmaceutical manufacturing technology, supporting the complex needs of global pharmaceutical partners.
Anthony Khan - Global Chief Revenue Officer, Business & Director
Anthony Khan, the Global Chief Revenue Officer, Business & Director at Asymchem, manages all revenue-generating activities and business development initiatives on a global scale. Khan directs strategies to expand Asymchem's client base among pharmaceutical companies, focusing on delivering comprehensive drug development and manufacturing services. This role involves cultivating key client relationships and identifying new market opportunities to drive revenue growth. The Global Chief Revenue Officer, Business & Director ensures that Asymchem's service offerings align with market demands and client needs, particularly in areas requiring innovative green solutions. Khan's leadership is instrumental in securing new partnerships and reinforcing Asymchem's position as a leading Contract Development and Manufacturing Organization. Anthony Khan's commercial acumen and strategic oversight are vital to the company's sustained financial performance and market expansion.
Explore Leadership Teams in Manufacturing
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Company Leadership
JJ
SK
RF
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
Company Leadership TM
CP
GP
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage each of its core therapeutic fields.
Company Leadership
MC
MA
AL
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Frequently Asked Questions Regarding Asymchem Top Executives and Leadership Team
Unlock more people and company data
